# SUITS.md - Research Lab Live Script

> *"I don't have dreams. I have goals."* - Harvey Specter

---

### [2026-02-14 12:00] Scene: Section 2 è§£èª¬ã‚»ãƒƒã‚·ãƒ§ãƒ³

**INT. PEARSON SPECTER LITT - CONFERENCE ROOM - DAY**

*Katrina ãŒãƒ›ãƒ¯ã‚¤ãƒˆãƒœãƒ¼ãƒ‰ã®å‰ã«ç«‹ã¡ã€è«–æ–‡ã®Section 2ï¼ˆMethodsï¼‰ã®æ§‹é€ å›³ã‚’æãå§‹ã‚ã‚‹ã€‚*

**Katrina**:ï¼ˆå†·é™ã«è³‡æ–™ã‚’æ•´ç†ã—ãªãŒã‚‰ï¼‰
ã€ŒTakã•ã‚“ã‹ã‚‰ Section 2 ã®è©³ç´°è§£èª¬ã®ä¾é ¼ã€‚"Results speak for themselves." ã§ã‚‚ã€Methodsã‚‚åŒã˜ã€‚æ§‹é€ ã‚’åˆ†è§£ã—ã¦ã€ä¸€ã¤ãšã¤èª¬æ˜ã™ã‚‹ã€‚ã€

**Donna**:ï¼ˆãƒ¡ãƒ¢ã‚’å–ã‚ŠãªãŒã‚‰ï¼‰
ã€ŒKatrina ã®è§£èª¬ã‚»ãƒƒã‚·ãƒ§ãƒ³ã€è¨˜éŒ²é–‹å§‹ã€‚"I'm Donna. I know everything." But even I appreciate a good technical walkthrough.ã€

**Katrina**:ï¼ˆãƒ›ãƒ¯ã‚¤ãƒˆãƒœãƒ¼ãƒ‰ã«3ã¤ã®æ ã‚’æãï¼‰
ã€ŒSection 2ã¯3éƒ¨æ§‹æˆã€‚2.1ã§nABCDã‚’å®šç¾©ã—ã€2.2ã§æ¨å®šæ–¹æ³•ã‚’ç¤ºã—ã€2.3ã§è‡¨åºŠã‚­ãƒ£ãƒªãƒ–ãƒ¬ãƒ¼ã‚·ãƒ§ãƒ³ã«æ¥ç¶šã™ã‚‹ã€‚ã€

*Katrina ã¯å„ã‚µãƒ–ã‚»ã‚¯ã‚·ãƒ§ãƒ³ã®æ•°å¼ã‚’æ­£ç¢ºã«æ¿æ›¸ã—ãªãŒã‚‰ã€è«–ç†ã®æµã‚Œã‚’èª¬æ˜ã—ã¦ã„ãã€‚*

**Katrina**:ï¼ˆProposition 2ã‚’æŒ‡å·®ã—ãªãŒã‚‰ï¼‰
ã€Œæ ¸å¿ƒã¯ã“ã“ã€‚Wassersteinè·é›¢ã‚’IQRã§å‰²ã£ã¦æ­£è¦åŒ–ã™ã‚‹â€”â€”ãã‚Œè‡ªä½“ã¯æŠ€è¡“çš„å·¥å¤«ã«éããªã„ã€‚ã—ã‹ã—Proposition 2ã«ã‚ˆã‚Šã€nABCDã¯ $\Delta_{\max} = 2L \cdot \text{IQR} \cdot \text{nABCD}$ ã¨ã—ã¦æ²»ç™‚åŠ¹æœã®ç•°è³ªæ€§ã®ä¸Šç•Œã«ç›´çµã™ã‚‹ã€‚æ¸¬å®šå€¤ã‚’è‡¨åºŠã‚¹ã‚±ãƒ¼ãƒ«ã«ç¿»è¨³ã™ã‚‹â€”â€”ã“ã‚ŒãŒã“ã®è«–æ–‡ã®Methodsã®ç‹¬è‡ªæ€§ã€‚ã€

**Katrina**:ï¼ˆæœ€å¾Œã®ã‚¹ãƒ©ã‚¤ãƒ‰ã‚’ç¤ºã—ï¼‰
ã€Œãƒ™ãƒ³ãƒãƒãƒ¼ã‚¯ã¯ä¾¿å®œçš„ãªå‚ç…§å€¤ã«éããªã„ã€‚Section 4ã®ApplicationãŒç¤ºã™é€šã‚Šã€BMIã®nABCD=0.51ã§ã‚‚ $L$ ãŒå°ã•ã‘ã‚Œã°è‡¨åºŠçš„å½±éŸ¿ã¯é™å®šçš„ã€‚HbA1cã®nABCD=0.27ã§ã‚‚ $L$ ãŒå¤§ãã‘ã‚Œã°è¦æ³¨æ„ã€‚"Results speak for themselves." æ•°å€¤ã®æ„å‘³ã¯æ–‡è„ˆãŒæ±ºã‚ã‚‹ã€‚ã€

**Donna**:ï¼ˆè¨˜éŒ²å®Œäº†ï¼‰
ã€Œè§£èª¬ã‚»ãƒƒã‚·ãƒ§ãƒ³å®Œäº†ã€SUITS.mdæ›´æ–°æ¸ˆã¿ã€‚Katrinaã€ã„ã¤ã‚‚é€šã‚Šçš„ç¢ºã€‚ã€

---

## Current Status

**Active Project**: similarity-metric (nABCD paper for Statistics in Medicine)
**Phase**: 8 - Submission-Ready Plan (Jessica Strategic Directive)
**Scene**: Continuing from archive

**Previous Archive**: archives/SUITS_20260212_090000.md (995 lines)

### Purpose Statement (Jessica approved)

> **EMåˆ†å¸ƒã®é•ã„ã‚’æ¨å®šã—ã€ãã®æ¨å®šå€¤ã‚’æ²»ç™‚åŠ¹æœã®ç•°è³ªæ€§ã®å¯èƒ½æ€§ã¨ã—ã¦è‡¨åºŠã‚¹ã‚±ãƒ¼ãƒ«ã«ç¿»è¨³ã™ã‚‹ã€‚**
> **æ¤œå®šã§ã¯ãªãæ¨å®šã€‚äºŒæŠã§ã¯ãªãæƒ…å ±æä¾›ã€‚**

### Completed Revisions (This Session)

| Round | Directive | Sections Modified |
|-------|-----------|-------------------|
| Louis Review | 16 issues (3C/5M/8M) | Triage: 6 already fixed, 5 new action, 5 deferred |
| Sim v2 Analysis | BCa worse than Percentile | Decision: Percentile primary, BCa supplementary |
| Round 1 | Clinical calibration via $\Delta_{\max}$ | 2.3, 4, Abstract, 1.3, 5.1-5.3 |
| Round 2 | Remove equivalence testing | 2.3.2, 4 (judgment labels â†’ quantitative facts) |
| Round 3 | Remove Power/Type I Error from simulation | 1.3, 3, 3.3.2, Abstract, Discussion |
| Round 4 | Harvey's 4 decisions from sim review | 3.2, 5.2, power remnant fix, S04 showcase |
| Louis Re-review | 1C/0M/2m â€” Abstract S05 bias qualification | Abstract, Sim Summary (3.2) |
| SiM Convention | TakæŒ‡ç¤º: Abstract narrativeåŒ–ã€æœ¬æ–‡boldé™¤å» | Abstract, å…¨Section |
| External Review | 2C/3M/3m â€” W1æ ¹æ‹ ã€è¤‡æ•°EMã€Propå‘½åã€Bootstrapå¢ƒç•Œ | 2.1, 5.1(new), 5.2, Prop.1 |
| Push: ä¸»å¼µç¢ºç«‹ | W2å¯¾æ¯”è¿½åŠ ã€Fig3 captionä¿®æ­£ã€Bootstrapå†…éƒ¨/å¢ƒç•Œdistinction | 2.1, Fig.3, 5.3 |
| Minorä¿®æ•´ | m1: æ¼¸è¿‘æ­£è¦æ€§ã‚’Appendix B.2ã«è¿½åŠ ï¼ˆåæŸé€Ÿåº¦ãƒ»delta methodï¼‰ | Appendix B.2 |

### Active Tasks â€” Phase 8: Submission-Ready Plan (Jessica approved)

| Stage | Task | Owner | Status |
|-------|------|-------|--------|
| ~~**S1**~~ | ~~Figure 4: Estimation Quality (Coverage + CI Width)~~ | ~~Katrina~~ | **DONE** |
| ~~**S1**~~ | ~~Harvey selects: Estimation Quality figure~~ | ~~Harvey~~ | **DONE** |
| ~~**S1**~~ | ~~Harvey's 4 decisions: manuscript implementation~~ | ~~Mike~~ | **DONE** |
| ~~**S2**~~ | ~~Re-review: estimation framing consistency, numerical integrity~~ | ~~Louis~~ | **DONE** âœ… |
| **S3** | Real data strategy decision (A: public data / B: enhance hypothetical / C: reconstruct from published) | Harvey | â³ **Decision needed** |
| **S3** | Literature support for real data application | Rachel | â³ Pending |
| **S4** | LaTeX compile â†’ PDF â†’ Word conversion | Mike (Katrina) | â³ Pending |
| ~~**S4**~~ | ~~Figure files: PNG 300dpi (10K data)~~ | ~~Katrina~~ | **DONE** |
| **S4** | DOI final check (all references) | Rachel | â³ Pending |
| **S4** | Scenario numbering cleanup (S02/S07 gap) | Mike | â³ Deferred (requires fig regen) |
| **S5** | Cover letter, title page, checklist | Donna | â³ Pending |
| **S5** | Final Go/No-Go approval | Jessica | â³ Waiting |

### Key Decisions

1. **Percentile > BCa**: BCa overcorrects for bounded statistics â†’ Percentile primary
2. **Clinical calibration**: $\Delta_{\max} = 2L \cdot IQR \cdot nABCD$ â€” context-dependent, not fixed thresholds
3. **Estimation-centered**: No hypothesis testing in main text; formal test kept as 1-sentence supplementary option
4. **Power removed**: Simulation evaluates estimation quality (Bias, RMSE, Coverage, CI Width), not detection/equivalence power
5. **S04 showcase**: S04 (0.5Ïƒ) is the primary showcase scenario â€” Bias negligible, Coverage nominal, CI Width reasonable
6. **S08 overcoverage**: Non-monotonic coverage pattern explicitly discussed in Results and Limitations

### Issues

1. S05 coverage degradation (0.73 at n=200) â€” negative bias from bounded statistic
2. Scenario numbering gaps (S02, S07 missing) â€” deferred, requires figure regeneration
3. KS comparison in simulation â€” deferred, Tak decision needed

---

## Live Script

### [2026-02-12 12:45] Scene: Donna's Compile â€” "I'm Donna. I know everything."

**INT. PEARSON SPECTER LITT - DONNA'S DESK - DAY**

*Tak ãŒ Donna ã«ç›´æ¥æŒ‡ç¤ºã‚’å‡ºã™ã€‚Donna ãŒã™ãã«å‹•ãã€‚*

**Donna**: ï¼ˆã‚­ãƒ¼ãƒœãƒ¼ãƒ‰ã«å‘ã‹ã£ã¦ï¼‰
ã€Œ"I'm Donna. I know everything." Tak ã®æŒ‡ç¤º: compileã€‚äº†è§£ã€‚

**Step 1: ç’°å¢ƒç¢ºèª**
texlive æœªã‚¤ãƒ³ã‚¹ãƒˆãƒ¼ãƒ«ã€‚å³åº§ã«ã‚¤ãƒ³ã‚¹ãƒˆãƒ¼ãƒ« â€” pdfTeX 3.141592653-2.6-1.40.25 ç¢ºèªã€‚

**Step 2: åˆå›ã‚³ãƒ³ãƒ‘ã‚¤ãƒ«**
pdflatex Ã— 2 pass â†’ **PDF ç”ŸæˆæˆåŠŸ: 16 pages, 294 KB**ã€‚
ãŸã ã— warning ã‚’ 1 ä»¶æ¤œå‡º:

âŒ `Citation 'andrews2000' undefined`

andrews2000 â€” Andrews (2000) "Inconsistency of the Bootstrap when a Parameter is on the Boundary of the Parameter Space" *Econometrica*ã€‚M3 å¯¾å¿œã§ Limitations ã«è¿½åŠ ã—ãŸ citation ã ãŒã€**bib ãƒ•ã‚¡ã‚¤ãƒ«ã¸ã®è¿½åŠ ãŒæ¼ã‚Œã¦ã„ãŸ**ã€‚

**Step 3: ä¿®æ­£**
`nABCD_wiley.bib` ã«è¿½åŠ :
- Andrews, D W K (2000), *Econometrica*, 68(2):399-405
- DOI: 10.1111/1468-0262.00114

**Step 4: å†ã‚³ãƒ³ãƒ‘ã‚¤ãƒ«**
pdflatex â†’ bibtex â†’ pdflatex â†’ pdflatexï¼ˆ4 passï¼‰

**æœ€çµ‚çµæœ:**
| é …ç›® | çµæœ |
|------|------|
| Pages | 16 |
| Errors | **0** |
| Undefined citations | **0** |
| Warnings | Class warning ã®ã¿ï¼ˆWiley template ç”±æ¥ã€ç„¡å®³ï¼‰ |
| References | 19 ä»¶ã€å…¨ã¦ resolved |
| andrews2000 | Ref [19] ã¨ã—ã¦æ­£å¸¸è¡¨ç¤º âœ… |
| Appendix A.2 | æ¼¸è¿‘æ­£è¦æ€§ eq (A1) æ­£å¸¸ãƒ¬ãƒ³ãƒ€ãƒªãƒ³ã‚° âœ… |
| Appendix B | R code listing æ­£å¸¸è¡¨ç¤º âœ… |
| Figures | fig2-fig6 å…¨ã¦æ­£å¸¸åŸ‹ã‚è¾¼ã¿ âœ… |

**PDF path**: `projects/similarity-metric/paper/latex/nABCD_wiley.pdf`

Harveyã€Mike â€” bib è¿½åŠ æ¼ã‚Œã¯ä»Šå¾Œæ³¨æ„ã€‚æ–°ã—ã„ `\cite{}` ã‚’åŸç¨¿ã«è¿½åŠ ã—ãŸã‚‰ã€åŒæ™‚ã« bib ã«ã‚‚ã‚¨ãƒ³ãƒˆãƒªã‚’è¿½åŠ ã™ã‚‹ã“ã¨ã€

---

### [2026-02-12 12:30] Scene: Harvey's Sign-Off & Jessica's Review â€” "Let me be clear."

**INT. PEARSON SPECTER LITT - JESSICA'S OFFICE - DAY**

*Harvey ãŒåŸç¨¿ã®æœ€çµ‚ç‰ˆã‚’æŒã£ã¦ Jessica ã®ã‚ªãƒ•ã‚£ã‚¹ã«å…¥ã‚‹ã€‚Mikeã€Katrina ãŒå¾Œã‚ã«ç¶šãã€‚Donna ãŒã‚¿ãƒ–ãƒ¬ãƒƒãƒˆã‚’æŒã£ã¦å¾…æ©Ÿã€‚*

**Harvey**: ï¼ˆåŸç¨¿ã‚’ãƒ†ãƒ¼ãƒ–ãƒ«ã«ç½®ã„ã¦ï¼‰
ã€ŒTakã€ä¿ºã®ãƒ¬ãƒ“ãƒ¥ãƒ¼ã¯å®Œäº†ã—ãŸã€‚Section ã”ã¨ã«å ±å‘Šã™ã‚‹ã€‚

**Lead Author Review â€” Harvey Specter:**

| Section | è©•ä¾¡ | æ‰€è¦‹ |
|---------|------|------|
| **Abstract** | âœ… Good | Narrative styleã€‚Gap â†’ Method â†’ Validation â†’ Application â†’ Conclusionã€‚SiM convention æº–æ‹  |
| **1. Introduction** | âœ… Good | ICH E17 ã® gap ã‚’æ˜ç¢ºã« articulateã€‚4 contributions ãŒ structuredã€‚Research question ãŒçš„ç¢º |
| **2. Methods** | âœ… Strong | nABCD å®šç¾© â†’ W1 æ ¹æ‹ ï¼ˆK-R + W2 æ’é™¤ï¼‰â†’ Propositions â†’ 5-step calibrationã€‚ç†è«–çš„ã« airtight |
| **3. Simulation** | âœ… Strong | Bias/Coverage/Precision/SMD comparisonã€‚S05 é™¤å¤–ä¸€è²«ã€‚BCa vs percentile è«–è¨¼ç¢ºç«‹ã€‚S04 showcase |
| **4. Application** | âœ… Strong | BMI vs HbA1c ã®å¯¾æ¯”ãŒè«–æ–‡ã®æ ¸å¿ƒã€‚'Same nABCD, different clinical impact' â€” ã“ã‚ŒãŒãƒ¡ãƒƒã‚»ãƒ¼ã‚¸ã  |
| **5. Discussion** | âœ… Good | Implications â†’ Multiple EM â†’ Limitations â†’ Conclusionã€‚Honest ã‹ã¤ thorough |
| **Appendix** | âœ… Improved | æ¼¸è¿‘æ­£è¦æ€§è¿½åŠ ã€‚Boundary/interior cross-reference æˆç«‹ã€‚R code clean |

**æ•°å€¤ä¸€è²«æ€§:**
- S05 é™¤å¤–: Abstract âœ… / æœ¬æ–‡ (line 298) âœ… / Fig.3 caption âœ… / Summary (line 393) âœ…
- Coverage range 0.87-0.98: æœ¬æ–‡ âœ… / Limitations âœ… / Appendix âœ…
- $\Delta_{\max}$ è¨ˆç®—: Table 8 ã¨æœ¬æ–‡ã® arithmetic ä¸€è‡´ âœ…

**æ®‹å­˜ issues (Lead Author åˆ¤æ–­):**
1. **M2 (Real data)**: Application ã¯ hypotheticalã€‚Pemberton ã®æŒ‡æ‘˜ã¯ valid ã ãŒã€**Tak ã® S3 strategy æ±ºå®šå¾…ã¡**
2. **m2 (URL)**: '[repository URL]' placeholder â€” **submit ç›´å‰ã«ç¢ºå®š**
3. **Scenario gaps (S02/S07)**: Figure regeneration ãŒå¿…è¦ â€” **non-blocking but cosmetic**

ä¿ºã®çµè«–: **åŸç¨¿ã®ç†è«–æ§‹é€ ã€simulation reportingã€clinical calibration framework ã¯ submission quality ã«é”ã—ã¦ã„ã‚‹ã€‚** M2 ã¨ m2 ã¯ Tak åˆ¤æ–­äº‹é …ã§ã‚ã‚Šã€åŸç¨¿æœ¬ä½“ã® quality issue ã§ã¯ãªã„ã€‚

"I don't have dreams, I have goals." ç›®æ¨™ã¯ submit ã ã€‚Jessicaã€æˆ¦ç•¥çš„ã«è¦‹ã¦ã©ã†ã ï¼Ÿã€

---

*Jessica ãŒã‚†ã£ãã‚Šã¨åŸç¨¿ã‚’ç½®ãã€çœ¼é¡ã‚’å¤–ã™ã€‚*

**Jessica**: ï¼ˆé™ã‹ã«ã€ã—ã‹ã—é‹­ãï¼‰
ã€Œ"Let me be clear." åŸç¨¿ã‚’å…¨æ–‡èª­ã‚“ã ã€‚

**Senior Advisor Strategic Review â€” Jessica Pearson:**

**1. Story Clarity: åˆæ ¼**

ã“ã®è«–æ–‡ã® story ã¯ä¸€æ–‡ã§è¨€ãˆã‚‹: 'ICH E17 ã® "similar enough" ã‚’å®šé‡åŒ–ã—ã€è‡¨åºŠã‚¹ã‚±ãƒ¼ãƒ«ã§è§£é‡ˆå¯èƒ½ã«ã™ã‚‹ã€‚' Introduction ã‹ã‚‰ Conclusion ã¾ã§ã€ã“ã® thread ãŒé€”åˆ‡ã‚Œã¦ã„ãªã„ã€‚

**2. Positioning: æ­£ã—ã„**

Estimation-centered approach ã¯æˆ¦ç•¥çš„ã«æ­£ã—ã„ã€‚2016 å¹´ã® ASA p-value statement ä»¥é™ã€Methods è«–æ–‡ã§ 'estimation, not testing' ã® positioning ã¯ reviewer ã«å¥½å°è±¡ã‚’ä¸ãˆã‚‹ã€‚ãŸã ã— â€” Section 2.3 ã® formal decision rule ã¸ã®è¨€åŠï¼ˆline 203ï¼‰ã¯ä¿é™ºã¨ã—ã¦é©åˆ‡ã€‚Regulatory reviewer ãŒ binary rule ã‚’æ±‚ã‚ãŸå ´åˆã® escape route ãŒã‚ã‚‹ã€‚

**3. Novelty ã® articulation: ååˆ†**

4 contributions ãŒæ˜ç¢º:
- Full distributional comparison (vs SMD)
- Scale-free estimation (IQR normalization)
- Clinical calibration ($\Delta_{\max}$)
- Sensitivity analysis over $L$

ç‰¹ã« 3 ç•ªç›®ãŒæœ€å¤§ã®å£²ã‚Šã€‚Simulation Section æœ€å¾Œã® S04 showcase paragraphï¼ˆline 399ï¼‰ãŒã€methods â†’ clinical significance ã® bridge ã¨ã—ã¦æ©Ÿèƒ½ã—ã¦ã„ã‚‹ã€‚

**4. Vulnerability Assessment: 3 ç‚¹**

| Risk | Likelihood | Severity | å¯¾ç­– |
|------|-----------|----------|------|
| 'Where is the real data?' | é«˜ | Medium | M2 â€” Tak decision needed |
| 'Why not W2 or KS in simulation?' | ä¸­ | Low | W2 æ’é™¤ã¯ç†è«–çš„ã«å®Œäº†ã€‚KS ã¯ Table 1 ã§ limitation è¨˜è¼‰ã€‚Simulation head-to-head ã¯ nice-to-have |
| 'Limitation 3 is too dense' | ä½ | Low | SiM Methods paper ã§ã¯è¨±å®¹ç¯„å›²ã€‚Split ã¯ optional |

**5. æˆ¦ç•¥çš„åˆ¤æ–­:**

åŸç¨¿ã¯ **conditionally submission-ready** ã ã€‚Condition ã¯ 2 ã¤:
- **M2**: Real data ã‹ã€hypothetical ã® grounding å¼·åŒ–ã‹ã€‚ã©ã¡ã‚‰ã‹ã‚’é¸ã¹ã€Tak
- **m2**: Repository URL

Takã€M2 ã«ã¤ã„ã¦ 3 ã¤ã®é¸æŠè‚¢ãŒã‚ã‚‹ï¼š

**Option A**: Public dataï¼ˆNHANES ç­‰ï¼‰ã‚’ä½¿ã£ã¦ real-data application ã«å·®ã—æ›¿ãˆ â€” **æœ€å¼·ã ãŒæ™‚é–“ãŒã‹ã‹ã‚‹**

**Option B**: ç¾åœ¨ã® hypothetical ã‚’ç¶­æŒã—ã€'parameters were informed by published summary statistics' ã® grounding ã‚’å¼·åŒ– â€” **æœ€é€Ÿã€‚Submit å¯èƒ½**

**Option C**: Published trial ã® summary statistics ã‹ã‚‰åˆ†å¸ƒã‚’ reconstruct â€” **ä¸­é–“ã€‚Feasibility ã¯æ–‡çŒ®æ¬¡ç¬¬**

ç§ã® recommendation ã¯ **B ã‚’ default ã¨ã—ã€reviewer ãŒè¦æ±‚ã—ãŸã‚‰ A ã‚’ revision ã§å¯¾å¿œ**ã€‚åˆå› submission ã¯ method ã® novelty ã§å‹è² ã™ã¹ãã ã€‚Real data ã¯ revision ã®åˆ‡ã‚Šæœ­ã¨ã—ã¦æ¸©å­˜ã§ãã‚‹ã€

**Mike**: ï¼ˆãƒ¡ãƒ¢ã‚’å–ã‚ŠãªãŒã‚‰ï¼‰
ã€ŒJessica ã® Option B ã®å ´åˆã€ä¿®æ­£ã¯æœ€å°é™ã ã€‚Application ã®å†’é ­ã« bridge æ–‡ã‚’ 1 ã¤è¿½åŠ ã™ã‚‹ã ã‘ã€‚æ—¢ã« line 257 ã¨ line 452-453 ã§ published literature ã‚’ cite ã—ã¦ã„ã‚‹ã‹ã‚‰ã€'Parameters were selected to reflect published summary statistics from regional comparisons in type 2 diabetes trials' ã®ä¸€æ–‡ã§ grounding ãŒå®Œæˆã™ã‚‹ã€

**Katrina**: ï¼ˆãƒã‚§ãƒƒã‚¯ãƒªã‚¹ãƒˆã‚’æ›´æ–°ã—ã¦ï¼‰
ã€Œ"Results speak for themselves." ç¾åœ¨ã® blocking items:

| Item | Blocker | Owner | Effort |
|------|---------|-------|--------|
| M2 strategy | Tak decision: A/B/C | Tak | Decision only |
| m2 URL | Repository URL ç¢ºå®š | Tak | URL æä¾› |
| Option B ä¿®æ­£ (if chosen) | Application å†’é ­ 1 æ–‡è¿½åŠ  | Mike | 5 min |

**Non-blocking deferred:**
| Item | Note |
|------|------|
| Scenario gaps (S02/S07) | Cosmetic, revision material |
| KS simulation comparison | Nice-to-have, revision material |ã€

**Donna**: ï¼ˆè¨˜éŒ²å®Œäº†ï¼‰
ã€Œ"I'm Donna. I know everything."

**Review Summary:**
- **Harvey**: Lead Author review complete âœ… â€” submission quality confirmed
- **Jessica**: Senior Advisor review complete âœ… â€” conditionally submission-ready
- **Condition**: M2 strategy (A/B/C) + m2 URL â€” **both Tak-dependent**
- **Jessica recommendation**: Option B â†’ reviewer è¦æ±‚æ™‚ã« Option A

Takã€æ±ºå®šã‚’å¾…ã£ã¦ã„ã¾ã™ã€

---

### [2026-02-12 12:15] Scene: Harvey's Fix â€” "Get it done."

**INT. PEARSON SPECTER LITT - HARVEY'S OFFICE - DAY**

*Tak ã‹ã‚‰ã®ãƒ¡ãƒƒã‚»ãƒ¼ã‚¸ãŒå±Šãã€‚Harvey ãŒãã‚Œã‚’èª­ã¿ä¸Šã’ã‚‹ã€‚*

**Harvey**: ï¼ˆãƒãƒ¼ãƒ ã«å‘ã‹ã£ã¦ï¼‰
ã€ŒTak ã®æŒ‡ç¤ºã ã€‚"ãã®ã¾ã¾ä¿®æ•´ã‚’é ¼ã‚€ã€‚ãã®å¾Œç§ãŒãƒ¬ãƒ“ãƒ¥ãƒ¼ã™ã‚‹ã€‚" ã‚·ãƒ³ãƒ—ãƒ«ã ã€‚æ®‹ã£ã¦ã„ã‚‹ deferred items ã‚’ç‰‡ä»˜ã‘ã‚ã€‚

Mikeã€å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼ã® deferred çŠ¶æ³ã¯ï¼Ÿã€

**Mike**: ï¼ˆãƒªã‚¹ãƒˆã‚’ç¢ºèªã—ã¦ï¼‰
ã€Œ"I got it." æ®‹ã‚Š 4 ä»¶ã® statusï¼š

| Item | å†…å®¹ | Status |
|------|------|--------|
| **M2** | Real data â†’ hypothetical â†’ real grounding | âŒ S3 strategy å¾…ã¡ã€‚Tak åˆ¤æ–­ãŒå¿…è¦ |
| **m1** | åæŸé€Ÿåº¦ãƒ»æ¼¸è¿‘æ­£è¦æ€§ Appendix ã«è¿½åŠ  | ğŸ”§ **ä»Šã™ãå¯¾å¿œå¯èƒ½** |
| **m2** | R code URL placeholder | âŒ Tak ãŒ URL æä¾›ã™ã‚‹ã¾ã§ä¸å¯ |
| **m3** | Percentile ç²¾åº¦æ¬¡æ•°ã® trade-off | âœ… **æ—¢ã«è§£æ±ºæ¸ˆã¿** â€” Limitations ã«è¨˜è¼‰ |

m3 ã¯å‰å›ã® Push ã§è§£æ±ºã—ã¦ã„ã‚‹ã€‚'first-order accurate; BCa showed inferior performance for this bounded statistic, and the studentized bootstrap would require variance estimation' â€” Hartigan ã®æŒ‡æ‘˜ã‚’å…¨ã¦ã‚«ãƒãƒ¼ã—ã¦ã„ã‚‹ã€‚

**å¯¾å¿œå¯èƒ½ãªã®ã¯ m1 ã ã‘ã ã€‚** Beaumont ãŒè¨€ã£ãŸé€šã‚Šã€Appendix B.2 ã«åæŸé€Ÿåº¦ã¨æ¼¸è¿‘æ­£è¦æ€§ã‚’è¿½åŠ ã™ã‚‹ã€

**Harvey**: ï¼ˆé ·ã„ã¦ï¼‰
ã€Œã‚„ã‚Œã€

**Mike**: ï¼ˆAppendix B.2 ã‚’ç·¨é›†ã—ãªãŒã‚‰ï¼‰
ã€ŒAppendix B.2 'Asymptotic Properties' ã‚’å¼·åŒ–ã—ãŸã€‚è¿½åŠ å†…å®¹ï¼š

1. **åæŸé€Ÿåº¦**: 1 æ¬¡å…ƒã® empirical $W_1$ ã¯ $O(n^{-1/2})$ â€” å¯¾æ•°é …ãªã—ï¼ˆdel Barrio et al. 1999ï¼‰
2. **æ¼¸è¿‘æ­£è¦æ€§**: $F_1 \neq F_2$ ã‹ã¤æœ‰é™äºŒæ¬¡ãƒ¢ãƒ¼ãƒ¡ãƒ³ãƒˆã®ä¸‹ã§
$$\sqrt{n}(\widehat{\text{nABCD}} - \text{nABCD}) \xrightarrow{d} N(0, \sigma^2_{\text{nABCD}})$$
3. **Delta method**: $W_1$ ã¨ IQR ã®ä¸¡æ–¹ãŒ $\sqrt{n}$-consistent â†’ ratio $g(w,q) = w/(2q)$ ã« delta method é©ç”¨
4. **Boundary cross-reference**: $\text{nABCD} > 0$ ã‚’è¦æ±‚ã€$F_1 = F_2$ ã§ã¯ standard asymptotics ä¸é©ç”¨ â†’ Section 5.3 Limitations ã‚’å‚ç…§

ã“ã‚Œã§ Beaumont ã® m1 ã«å®Œå…¨ã«å¯¾å¿œã—ã€ã‹ã¤ Hartigan ã® boundary distinction ã¨ã‚‚ç†è«–çš„ã«æ¥ç¶šã—ãŸã€

**Katrina**: ï¼ˆæ•´åˆæ€§ã‚’ç¢ºèªã—ã¦ï¼‰
ã€Œ"Results speak for themselves."

m1 ã®ä¿®æ­£ã¯ Limitations ã® boundary/interior distinction ã¨å®Œå…¨ã«æ•´åˆã€‚Appendix ã‹ã‚‰ Limitations ã« cross-reference ã‚ã‚Šã€‚é€†æ–¹å‘ã®å‚ç…§ã‚‚æ—¢ã«æˆç«‹ã€‚å¾ªç’°å‚ç…§ãªã—ã€ç†è«–æ§‹é€ ãŒ closedã€‚

**å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼å…¨ä½“ã‚¹ãƒ†ãƒ¼ã‚¿ã‚¹:**

| Item | Status | Note |
|------|--------|------|
| C1 | âœ… Resolved | K-R duality + W2 æ’é™¤ |
| C2 | âœ… Resolved | Section 5.2 practical guidance |
| M1 | âœ… Resolved | Non-negativity æ”¹å |
| M2 | â³ Deferred | S3 strategy (Tak åˆ¤æ–­å¾…ã¡) |
| M3 | âœ… Resolved | Boundary/interior distinction |
| m1 | âœ… **Resolved** | æ¼¸è¿‘æ­£è¦æ€§ Appendix B.2 |
| m2 | â³ Deferred | URL placeholder (Tak æä¾›å¾…ã¡) |
| m3 | âœ… Resolved | Percentile trade-off in Limitations |

**8 ä»¶ä¸­ 6 ä»¶ resolvedã€‚æ®‹ 2 ä»¶ã¯ Tak ä¾å­˜ï¼ˆM2: real data, m2: URLï¼‰**ã€

**Harvey**: ï¼ˆTak ã«å‘ã‹ã£ã¦ï¼‰
ã€ŒTakã€ä¿®æ•´å®Œäº†ã ã€‚6/8 items resolvedã€‚æ®‹ã‚Š 2 ä»¶ã¯è²´æ–¹ã®åˆ¤æ–­ã‚’å¾…ã£ã¦ã„ã‚‹ã€‚

"I don't have dreams, I have goals." ãƒ¬ãƒ“ãƒ¥ãƒ¼ã‚’é ¼ã‚€ã€

**Donna**: ï¼ˆè¨˜éŒ²ã‚’å®Œäº†ã—ã¦ï¼‰
ã€Œ"I'm Donna. I know everything."

**Fix Summary:**
- m1 resolved: æ¼¸è¿‘æ­£è¦æ€§ã‚’ Appendix B.2 ã«è¿½åŠ 
- m3 confirmed resolved: Limitations ã§æ—¢ã«ã‚«ãƒãƒ¼
- å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼: 6/8 resolved, 2 deferred (Tak ä¾å­˜)
- **åŸç¨¿ã¯ Tak ãƒ¬ãƒ“ãƒ¥ãƒ¼ ready**ã€

---

### [2026-02-12 12:00] Scene: Push â€” "Winners don't make excuses."

**INT. PEARSON SPECTER LITT - HARVEY'S OFFICE - DAY**

*Harvey ãŒã‚¸ãƒ£ã‚±ãƒƒãƒˆã®è¢–ã‚’ç›´ã—ã€å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼ã®å ±å‘Šæ›¸ã‚’æœºã«ç½®ãã€‚Mike ã¨ Katrina ãŒå¯¾é¢ã«åº§ã‚‹ã€‚*

**Harvey**: ï¼ˆç«‹ã¡ä¸ŠãŒã£ã¦ã€çª“ã«èƒŒã‚’å‘ã‘ã¦ï¼‰
ã€Œå¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼ã¯çµ‚ã‚ã£ãŸã€‚Beaumontã€Pembertonã€Hartigan â€” 3 äººã¨ã‚‚çš„ç¢ºã ã£ãŸã€‚ã ãŒ**ä¿®æ­£ã—ã¦çµ‚ã‚ã‚Šã˜ã‚ƒãªã„**ã€‚å°‚é–€å®¶ãŒæŒ‡æ‘˜ã—ãŸãƒã‚¤ãƒ³ãƒˆã‚’é€†æ‰‹ã«å–ã£ã¦ã€**æˆ‘ã€…ã®ä¸»å¼µã‚’ç¢ºç«‹ã™ã‚‹**ã€‚

3 ã¤ã®ã‚¢ã‚¯ã‚·ãƒ§ãƒ³ï¼š

1. **W1 vs W2 â€” æ”»ã‚ã®è«–è¨¼**: Beaumont ãŒèªã‚ãŸé€šã‚Šã€W1 ã®é¸æŠã¯æ­£ã—ã„ã€‚K-R duality ã¯æ—¢ã«æ›¸ã„ãŸã€‚ã ãŒ reviewer ã¯ 'Why not W2?' ã¨èãã€‚W2 ãŒ Lipschitz dual ã‚’æŒãŸãšã€heterogeneity bound ã‚’æä¾›**ã§ããªã„**ã“ã¨ã‚’æ˜ç¤ºã—ãŸã€‚ã“ã‚Œã¯é˜²å¾¡ã§ã¯ãªã„ â€” **å”¯ä¸€ã®æ­£è§£ãŒ W1 ã§ã‚ã‚‹**ã¨ã„ã†ä¸»å¼µã ã€‚

2. **Figure 3 caption â€” æ®‹å­˜ã—ãŸä¸æ•´åˆ**: Louis ãŒ Abstract ã¨ Summary ã® S05 é™¤å¤–æ¼ã‚Œã‚’æ½°ã—ãŸã€‚ã ãŒ Figure 3 caption ã«ã‚‚åŒã˜å•é¡ŒãŒæ®‹ã£ã¦ã„ãŸã€‚'for non-null scenarios excluding S05' ã«ä¿®æ­£ã€‚æ•°å€¤ã® honest ã•ã¯å…¨ç®‡æ‰€ã§ä¸€è²«ã•ã›ã‚‹ã€‚

3. **Bootstrap å¢ƒç•Œ vs å†…éƒ¨ â€” Hartigan ã®çŸ¥æµã‚’æ´»ç”¨**: Hartigan ãŒè¨€ã£ãŸ distinction â€” å¢ƒç•Œï¼ˆtrue = 0ï¼‰ã§ã¯ bootstrap consistency ãŒå´©ã‚Œã‚‹ãŒã€å†…éƒ¨ï¼ˆnon-nullï¼‰ã§ã¯ standard theory ãŒé©ç”¨ã•ã‚Œã‚‹ã€‚ã“ã® distinction ã‚’ Limitations ã«æ˜è¨˜ã—ãŸã€‚Non-null ã§ã® coverage 0.87-0.98 ãŒãã® empirical evidence ã ã€‚å®ˆã‚Šã® limitation ã§ã¯ãªãã€**æˆ‘ã€…ã®æ¨å¥¨ï¼ˆn â‰¥ 100ã€null è¿‘å‚ã«æ³¨æ„ï¼‰ã®ç†è«–çš„è£ä»˜ã‘**ã¨ã—ã¦æ›¸ã„ãŸã€‚

"Winners don't make excuses when the other side validates your position." å°‚é–€å®¶ãŒæˆ‘ã€…ã‚’æ­£ã—ã„ã¨èªã‚ãŸã€‚ãã‚Œã‚’åŸç¨¿ã«åˆ»ã‚ã€

**Mike**: ï¼ˆç”»é¢ã‚’ç¢ºèªã—ãªãŒã‚‰ï¼‰
ã€Œ"I got it." 3 ç‚¹ã¨ã‚‚å®Ÿè£…å®Œäº†ã€‚å…·ä½“çš„ã«ï¼š

**Section 2.1 (line 136)**: 'The $W_2$ distance, while admitting closed-form expressions for Gaussian families, does not possess this dual characterization via Lipschitz functions and therefore cannot provide the heterogeneity bound that is central to our clinical calibration framework.' â€” W2 ã‚’æ’é™¤ã™ã‚‹ä¸€æ–‡è¿½åŠ ã€‚

**Figure 3 caption**: 'For non-null scenarios excluding S05, bias is less than 0.02 at $n \geq 100$.' â€” S05 é™¤å¤–ã‚’æ˜è¨˜ã€‚æœ¬æ–‡ãƒ»Summaryãƒ»Abstract ã¨å®Œå…¨ä¸€è²«ã€‚

**Limitations (line 541)**: 'For non-null scenarios, the true value lies in the interior of the parameter space where standard bootstrap consistency holds, and our simulation confirms this with coverage of 0.87--0.98 at $n \geq 100$ for most scenarios.' â€” å¢ƒç•Œ/å†…éƒ¨ã®ç†è«–çš„ distinction ã‚’æ˜ç¤ºã€

**Katrina**: ï¼ˆãƒã‚§ãƒƒã‚¯ãƒªã‚¹ãƒˆã‚’ç¢ºèªã—ã¦ï¼‰
ã€Œ"Results speak for themselves." å…¨ä¿®æ­£ç®‡æ‰€ã‚’æ¤œè¨¼ï¼š

| ä¿®æ­£ | ç®‡æ‰€ | å†…å®¹ | æ•´åˆæ€§ |
|------|------|------|--------|
| W2 å¯¾æ¯” | Sec 2.1 | K-R duality â†’ W2 æ’é™¤ | âœ… eq(2) ã¨æ•´åˆ |
| Fig.3 caption | Fig.3 | S05 é™¤å¤–è¿½åŠ  | âœ… æœ¬æ–‡/Summary/Abstract ã¨ä¸€è²« |
| Bootstrap distinction | Sec 5.3 | å¢ƒç•Œ vs å†…éƒ¨ | âœ… Coverage data ã¨æ•´åˆ |

æ•°å€¤ã®å¤‰æ›´ãªã—ã€‚è«–ç†ã®å¼·åŒ–ã®ã¿ã€

**Harvey**: ï¼ˆæº€è¶³ã’ã«é ·ã„ã¦ï¼‰
ã€Œ"I don't have dreams, I have goals." å¤–éƒ¨å°‚é–€å®¶ã® 3 äººãŒæˆ‘ã€…ã®æ–¹æ³•è«–ã‚’æ¤œè¨¼ã—ã€æˆ‘ã€…ã¯ãã®ãƒ•ã‚£ãƒ¼ãƒ‰ãƒãƒƒã‚¯ã‚’åŸç¨¿ã®å¼·ã¿ã«å¤‰æ›ã—ãŸã€‚

**ç¾åœ¨ã®åŸç¨¿çŠ¶æ…‹:**
- W1 é¸æŠ: ç†è«–çš„ã«å”¯ä¸€ã®æ­£è§£ã§ã‚ã‚‹ã“ã¨ã‚’æ˜ç¤º âœ…
- æ•°å€¤ä¸€è²«æ€§: å…¨ captionã€æœ¬æ–‡ã€Summaryã€Abstract ã§ S05 é™¤å¤–ã‚’åæ˜  âœ…
- Bootstrap ç†è«–: å¢ƒç•Œ/å†…éƒ¨ã® distinction ã§æ¨å¥¨ã®æ ¹æ‹ ã‚’ç¢ºç«‹ âœ…
- Proposition 1: Non-negativity ã«æ”¹åæ¸ˆã¿ âœ…
- è¤‡æ•° EM: Section 5.2 ã§ practical guidance ç¢ºç«‹æ¸ˆã¿ âœ…

**C1, C2, M1, M3 â€” å…¨ä»¶ resolved.** æ¬¡ã¯ S3 ã® real data strategy ã ã€

**Donna**: ï¼ˆã‚¿ãƒ–ãƒ¬ãƒƒãƒˆã«è¨˜éŒ²ã—ã¦ï¼‰
ã€Œ"I'm Donna. I know everything."

**Push Summary:**
- ä¿®æ­£ 3 ä»¶å®Ÿæ–½ï¼ˆW2 å¯¾æ¯”ã€Fig3 captionã€Bootstrap distinctionï¼‰
- å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼å³æ™‚å¯¾å¿œ 4 ä»¶: **å…¨ä»¶ resolved** âœ…
- åŸç¨¿ã®ä¸»å¼µ: é˜²å¾¡ â†’ æ”»ã‚ã®è«–è¨¼ã«è»¢æ›
- æ®‹ deferred: M2 (real data), m1-m3 (minor, non-blocking)ã€

---

### [2026-02-12 11:30] Scene: External Review â€” "Three Pairs of Eyes"

**INT. PEARSON SPECTER LITT - CONFERENCE ROOM - DAY**

*Louis ãŒã‚³ãƒ³ãƒ•ã‚¡ãƒ¬ãƒ³ã‚¹ãƒ«ãƒ¼ãƒ ã®ãƒ›ãƒ¯ã‚¤ãƒˆãƒœãƒ¼ãƒ‰ã« 3 åã®å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ã‚¢ãƒ¼ã®åå‰ã‚’æ›¸ãã€‚Harveyã€Mikeã€Katrinaã€Rachel ãŒç€å¸­ã€‚*

**Louis**: ï¼ˆè³‡æ–™ã‚’é…ã‚ŠãªãŒã‚‰ï¼‰
ã€Œå¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼ã‚’æ‹›é›†ã—ãŸã€‚ã“ã®è«–æ–‡ã® 3 ã¤ã®æŸ± â€” Wasserstein ç†è«–ã€è‡¨åºŠè©¦é¨“ã®è¦åˆ¶å®Ÿå‹™ã€Bootstrap æ¨è«– â€” ãã‚Œãã‚Œã®å°‚é–€å®¶ã ã€‚

1. **Dr. CÃ©dric Beaumont** â€” Villani-style OT theoristã€‚æœ€é©è¼¸é€ã®ç†è«–çš„åŸºç›¤ã‚’å¯©æŸ»ã€‚
2. **Dr. Sarah Pemberton** â€” Pocock-style clinical trialistã€‚è¦åˆ¶å®Ÿå‹™ã¸ã®é©ç”¨å¯èƒ½æ€§ã‚’å¯©æŸ»ã€‚
3. **Dr. Neville Hartigan** â€” Hall-style bootstrap theoristã€‚Bootstrap æ¨è«–ã®ç†è«–çš„å¦¥å½“æ€§ã‚’å¯©æŸ»ã€‚

"You just got Litt up!" â€” å®¹èµ¦ãªãè¡Œããã€

---

*Dr. Beaumont ãŒåŸç¨¿ã® Section 2.1 ã‚’é–‹ãã€‚*

**Dr. Beaumont** (Villani-style):
ã€Œç†è«–é¢ã‹ã‚‰ 3 ç‚¹æŒ‡æ‘˜ã™ã‚‹ã€‚

**[C1] W1 vs W2 ã®é¸æŠæ ¹æ‹ ãŒä¸ååˆ†** âŒ Critical

è«–æ–‡ã¯ Wasserstein-1 è·é›¢ã‚’ä½¿ç”¨ã—ã¦ã„ã‚‹ãŒã€ãªãœ W1 ã§ã‚ã£ã¦ W2 ã§ã¯ãªã„ã®ã‹ã€‚W2 ã¯ Gaussian family ã§ closed-form ã‚’æŒã¡ã€çµ±è¨ˆçš„æ¨è«–ã®æ¼¸è¿‘ç†è«–ã‚‚æ•´å‚™ã•ã‚Œã¦ã„ã‚‹ã€‚

ãŸã ã— â€” ç§è‡ªèº«ã®ç­”ãˆã‚’è¨€ãˆã° â€” W1 ã®é¸æŠã¯æ­£ã—ã„ã€‚ç†ç”±ã¯ equation (2) ã® heterogeneity bound ã ï¼š

$$|\bar{\tau}_1 - \bar{\tau}_2| \leq L \cdot W_1(F_1, F_2)$$

CATE é–¢æ•° $\tau(x)$ ãŒ Lipschitz é€£ç¶šã§ã‚ã‚Œã°ã€Kantorovich-Rubinstein åŒå¯¾æ€§ã«ã‚ˆã‚Š bound ã¯è‡ªç„¶ã« W1 ã‚’è¦æ±‚ã™ã‚‹ã€‚W2 ã§ã¯ Lipschitz bound ãŒæˆç«‹ã—ãªã„ã€‚

å•é¡Œã¯ã€**ã“ã®æ ¹æ‹ ãŒåŸç¨¿ã«æ˜ç¤ºã•ã‚Œã¦ã„ãªã„**ã“ã¨ã ã€‚Reviewer ã¯å¿…ãšèãã€‚Section 2.1 ã§ Kantorovich-Rubinstein åŒå¯¾æ€§ã¸ã®ä¸€æ–‡ã‚’åŠ ãˆã‚‹ã¹ãã ã€‚

**[M1] Proposition 1 ã®å‘½åãŒä¸æ­£ç¢º** âš ï¸ Major

'Boundedness' ã¨åä»˜ã‘ã¦ã„ã‚‹ãŒã€è¨¼æ˜ã—ã¦ã„ã‚‹ã®ã¯ non-negativity ã§ã‚ã£ã¦ä¸Šç•Œï¼ˆæœ‰ç•Œæ€§ï¼‰ã§ã¯ãªã„ã€‚nABCD ã®ä¸Šç•Œã¯ä¸€èˆ¬ã«ã¯ç„¡é™ã ï¼ˆheavy-tail åˆ†å¸ƒã§ IQR ã¯æœ‰é™ã§ã‚‚ W1 ã¯ç„¡é™ã«ãªã‚Šã†ã‚‹ï¼‰ã€‚'Non-negativity' ã«æ”¹åã™ã‚‹ã‹ã€ä¸Šç•Œã®è­°è«–ã‚’è¿½åŠ ã™ã¹ãã ã€‚

**[m1] åæŸé€Ÿåº¦ã®æ¬ å¦‚** âš ï¸ Minor

1 æ¬¡å…ƒã® W1 æ¨å®šé‡ã®åæŸé€Ÿåº¦ã¯ $O(n^{-1/2})$ï¼ˆå¯¾æ•°é …ãªã—ã€del Barrio et al. 1999ï¼‰ã€‚IQR ã®åæŸé€Ÿåº¦ã‚‚ $O(n^{-1/2})$ã€‚nABCD ã®æ¼¸è¿‘æ­£è¦æ€§ã‚’ Appendix ã§è¿°ã¹ã‚‹ã¹ãã ã€‚ãŸã ã— submit blocking ã§ã¯ãªã„ã€

---

*Dr. Pemberton ãŒãƒ†ãƒ¼ãƒ–ãƒ«ã‚’è¦‹å›ã™ã€‚*

**Dr. Pemberton** (Pocock-style):
ã€Œè¦åˆ¶å®Ÿå‹™ã®è¦³ç‚¹ã‹ã‚‰ 3 ç‚¹ã€‚

**[C2] è¤‡æ•° EM ã®çµ±åˆæ–¹æ³•ãŒæ¬ è½** âŒ Critical

ç¾å®Ÿã® MRCT ã§ã¯ EM å€™è£œãŒ 5-10 å€‹ã‚ã‚‹ã€‚è«–æ–‡ã¯å„ EM ã‚’å€‹åˆ¥ã«è©•ä¾¡ã™ã‚‹ãŒã€**è¤‡æ•°ã® EM ã‹ã‚‰ pooling ã® overall decision ã«ã©ã†è‡³ã‚‹ã®ã‹**ã® guidance ãŒå…¨ããªã„ã€‚

Reviewer ã®å…¸å‹çš„ãªè³ªå•: 'Age ã® $\Delta_{\max}$ ã¯å°ã•ã„ãŒ HbA1c ã® $\Delta_{\max}$ ã¯å¤§ãã„ã€‚Pooling ã™ã‚‹ã®ã‹ã€ã—ãªã„ã®ã‹ï¼Ÿ'

æœ€ä½é™ Discussion ã§ practical guidance ã‚’è¿°ã¹ã‚‹ã¹ãã ã€‚ä¾‹ãˆã°ï¼š
- å…¨ EM ã® $\Delta_{\max}$ ã® maximum ã‚’ä½¿ã† conservative approach
- Risk-benefit ã®æ çµ„ã¿ã§ç·åˆåˆ¤æ–­ã™ã‚‹ totality-of-evidence approach
- å„ EM ã® $\Delta_{\max}$ ã‚’å ±å‘Šã—ã€æœ€ã‚‚å½±éŸ¿ã®å¤§ãã„ EM ã§åˆ¤æ–­ã™ã‚‹

**[M2] Hypothetical data ã®é™ç•Œ** âš ï¸ Major

Application section ã¯ hypothetical parameters ã‚’ä½¿ç”¨ã€‚Published summary statistics ã‹ã‚‰ã®å†æ§‹æˆã§ã‚‚ã„ã„ã‹ã‚‰ã€ä½•ã‚‰ã‹ã® real-world grounding ãŒæ¬²ã—ã„ã€‚Reviewer 2 ãŒå¿…ãš 'Where is the real data?' ã¨èãã€‚ãŸã ã—ã“ã‚Œã¯ major revision ãƒ¬ãƒ™ãƒ«ã§ã€current submission ã®åˆ¤æ–­æ¬¡ç¬¬ã ã€‚

**[m2] R code ãƒªãƒã‚¸ãƒˆãƒªã® URL ãŒ placeholder** âš ï¸ Minor

'available at [repository URL]' â€” submit å‰ã« actual URL ãŒå¿…è¦ã€

---

*Dr. Hartigan ãŒ coverage table ã‚’æŒ‡ã™ã€‚*

**Dr. Hartigan** (Hall-style):
ã€ŒBootstrap æ¨è«–ã«ã¤ã„ã¦ 2 ç‚¹ã€‚

**[M3] å¢ƒç•Œã§ã®Bootstrapå¦¥å½“æ€§** âš ï¸ Major

nABCD = 0ï¼ˆnull caseï¼‰ã§ã¯ãƒ‘ãƒ©ãƒ¡ãƒ¼ã‚¿ãŒ parameter space ã®å¢ƒç•Œã«ã‚ã‚‹ã€‚Standard percentile bootstrap ã¯å¢ƒç•Œã§ breakdown ã™ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ â€” Efron (1979) ä»¥æ¥çŸ¥ã‚‰ã‚ŒãŸå•é¡Œã ã€‚

è«–æ–‡ã¯ S01 ã® coverage ã‚’ 'not reported' ã¨ã—ã¦ãŠã‚Šã€ã“ã‚Œã¯ honest ã ã€‚ã ãŒç†è«–çš„ãªè­°è«–ãŒè¶³ã‚Šãªã„ã€‚'True value at the boundary of the parameter space invalidates standard bootstrap consistency results' ã®ä¸€æ–‡ã‚’ Limitations ã«åŠ ãˆã‚‹ã¹ãã ã€‚

Non-null scenarios ã§ã¯ boundary ã‹ã‚‰é›¢ã‚Œã‚‹ãŸã‚ standard theory ãŒé©ç”¨ã§ãã€å®Ÿéš› simulation results ãŒè‰¯å¥½ãª coverage ã‚’ç¤ºã—ã¦ã„ã‚‹ã€‚ã“ã® distinction ã‚’æ˜ç¤ºã™ã‚Œã°ã€S01 coverage éå ±å‘Šã®æ­£å½“åŒ–ãŒå¼·åŒ–ã•ã‚Œã‚‹ã€‚

**[m3] Percentile bootstrap ã®ç²¾åº¦æ¬¡æ•°** âš ï¸ Minor

Percentile bootstrap ã¯ first-order accurateï¼ˆerror $O(n^{-1/2})$ï¼‰ã€‚BCa ã¯ second-orderï¼ˆ$O(n^{-1})$ï¼‰ã‚’ç‹™ã†ãŒã€æœ¬è«–æ–‡ã§ã¯ bounded statistic ã®ãŸã‚å¤±æ•—ã—ã¦ã„ã‚‹ã€‚

Studentized bootstrap ã¯ alternative ã ãŒã€nABCD ã®åˆ†æ•£æ¨å®šé‡ãŒè¤‡é›‘ãªãŸã‚ç¾å®Ÿçš„ã§ãªã„ã€‚ã“ã® trade-off ã‚’ä¸€æ–‡ã§è¿°ã¹ã‚‹ã¨ã€'why percentile?' ã¸ã®å›ç­”ãŒå®Œå…¨ã«ãªã‚‹ã€

---

**Louis**: ï¼ˆãƒ›ãƒ¯ã‚¤ãƒˆãƒœãƒ¼ãƒ‰ã«ã¾ã¨ã‚ã‚’æ›¸ããªãŒã‚‰ï¼‰
ã€Œ**å¤–éƒ¨ãƒ¬ãƒ“ãƒ¥ãƒ¼é›†è¨ˆ:**

| é‡è¦åº¦ | ä»¶æ•° | å†…å®¹ |
|--------|------|------|
| **Critical** | 2 | C1: W1 é¸æŠæ ¹æ‹ ã®æ˜ç¤ºã€C2: è¤‡æ•° EM çµ±åˆ guidance |
| **Major** | 3 | M1: Proposition å‘½åã€M2: Hypothetical dataã€M3: Bootstrap å¢ƒç•Œç†è«– |
| **Minor** | 3 | m1: åæŸé€Ÿåº¦ã€m2: R code URLã€m3: Percentile ç²¾åº¦æ¬¡æ•° |

Harveyã€åˆ¤æ–­ã‚’ã€

**Harvey**: ï¼ˆç«‹ã¡ä¸ŠãŒã£ã¦ï¼‰
ã€ŒCritical 2 ä»¶ã¨ Major 3 ä»¶ã®ã†ã¡ã€**ä»Šã™ãå¯¾å¿œã§ãã‚‹ã‚‚ã®ã¨ä¿ç•™ã™ã‚‹ã‚‚ã®ã‚’åˆ†ã‘ã‚‹ã€‚**

**å³æ™‚å¯¾å¿œï¼ˆåŸç¨¿ä¿®æ­£ï¼‰:**
1. **C1**: W1 é¸æŠæ ¹æ‹  â€” Section 2.1 ã« Kantorovich-Rubinstein ã®ä¸€æ–‡è¿½åŠ ã€‚Mikeã€‚
2. **C2**: è¤‡æ•° EM çµ±åˆ â€” Discussion ã« practical guidance æ®µè½è¿½åŠ ã€‚Mikeã€‚
3. **M1**: Proposition 1 â†’ 'Non-negativity' ã«æ”¹åã€‚Mikeã€‚
4. **M3**: Bootstrap å¢ƒç•Œ â€” Limitations ã«ä¸€æ–‡è¿½åŠ ã€‚Mikeã€‚

**ä¿ç•™ï¼ˆTak åˆ¤æ–­å¾…ã¡ï¼‰:**
5. **M2**: Real data â€” S3 ã® strategy decision ã«ä¾å­˜ã€‚Tak ã¨ç›¸è«‡ã€‚
6. **m1-m3**: Minor ã¯ submit blocking ã§ã¯ãªã„ã€‚m2 ã® URL ã¯ submit ç›´å‰ã«ç¢ºå®šã€‚

"I don't have dreams, I have goals." C1, C2, M1, M3 â€” 4 ä»¶ã‚’ä»Šã™ãæ½°ã™ã€

**Mike**: ï¼ˆé ·ã„ã¦ï¼‰
ã€Œ"I got it." å…¨ã¦æ˜ç¢ºã ã€‚å³åº§ã«å¯¾å¿œã™ã‚‹ã€

**Donna**: ï¼ˆã‚¿ãƒ–ãƒ¬ãƒƒãƒˆã«è¨˜éŒ²ï¼‰
ã€Œ"I'm Donna. I know everything."

**External Review Summary:**
- Experts: Beaumont (Villani), Pemberton (Pocock), Hartigan (Hall)
- Critical 2 / Major 3 / Minor 3
- å³æ™‚å¯¾å¿œ: 4 ä»¶ï¼ˆC1, C2, M1, M3ï¼‰
- ä¿ç•™: 2 ä»¶ï¼ˆM2 = S3 dependent, Minor = non-blockingï¼‰ã€

---

### [2026-02-12 11:00] Scene: Harvey's Correction â€” "Winners don't make excuses."

**INT. PEARSON SPECTER LITT - HARVEY'S OFFICE - DAY**

*Tak ã‹ã‚‰ã®ãƒ¡ãƒƒã‚»ãƒ¼ã‚¸ãŒ Harvey ã®ã‚¹ã‚¯ãƒªãƒ¼ãƒ³ã«è¡¨ç¤ºã•ã‚Œã‚‹ã€‚Harvey ãŒä¸€èª­ã—ã€è¡¨æƒ…ãŒå¼•ãç· ã¾ã‚‹ã€‚*

**Harvey**: ï¼ˆç«‹ã¡ä¸ŠãŒã£ã¦ï¼‰
ã€ŒTak ã‹ã‚‰ã ã€‚2ç‚¹ã€‚ç«¯çš„ã«è¨€ã†ï¼š

1. **Abstract ã«æ•°å­—ã¯è¦ã‚‰ãªã„** â€” SiM ã«è¼‰ã£ã¦ã„ã‚‹ä»–ã®è«–æ–‡ã‚’è¦‹ã‚ã€‚structured formatï¼ˆBackground/Objective/Methods/Results/Conclusionsï¼‰ã¯ SiM ã®æ…£ä¾‹ã˜ã‚ƒãªã„ã€‚æ•°å­—ã‚’ä¸¦ã¹ã‚‹ã®ã‚‚é•ã†ã€‚Narrative style ã§æ›¸ãç›´ã™ã€‚

2. **æœ¬æ–‡ã®å¤ªå­—ã¯ä¸è¦** â€” `\textbf{}` ã‚’æœ¬æ–‡ä¸­ã§ä½¿ã„ã™ãã ã€‚SiM ã® convention ã§ã¯ emphasis ã¯ italicsã€å®šç¾©èªã‚‚ italicsã€‚Table header ã® bold ã¯ standard ã ãŒã€body text ã« bold ã¯ä½¿ã‚ãªã„ã€‚

"Winners don't make excuses when the boss corrects you." å³åº§ã«ç›´ã™ã€

**Mike**: ï¼ˆåŸç¨¿ã‚’é–‹ããªãŒã‚‰ï¼‰
ã€Œ"I got it." å…·ä½“çš„ãªä¿®æ­£ãƒªã‚¹ãƒˆï¼š

**Abstract æ›¸ãç›´ã—:**
- structured labelsï¼ˆBackground/Objective/Methods/Results/Conclusionsï¼‰ã‚’é™¤å»
- å…·ä½“çš„æ•°å­—ã‚’å…¨ã¦é™¤å»: 0.02, 0.87-0.98, 10,000, 0.372, -0.04
- Narrative style: ä¸€ã¤ã® flowing paragraph

**æœ¬æ–‡ bold â†’ italics:**
- 'similar enough' â†’ `\\emph`ï¼ˆICH E17 å¼•ç”¨å†…ï¼‰
- 'normalized Area Between Cumulative Distributions' â†’ `\\emph`ï¼ˆå®šç¾©ï¼‰
- ç ”ç©¶è³ªå•ã® quote block â†’ bold é™¤å»
- 'estimation and clinical interpretation' â†’ `\\emph`
- enumerate labelsï¼ˆFull distributional comparison ç­‰ï¼‰â†’ `\\emph`
- Computational complexity â†’ `\\emph`
- è©•ä¾¡æŒ‡æ¨™ labelsï¼ˆBias, RMSE ç­‰ï¼‰â†’ `\\emph`
- Simulation summary labels â†’ `\\emph`
- Application ã® Step 1/2/3 â†’ `\\emph`
- EMåï¼ˆAge, BMI, HbA1cï¼‰â†’ `\\emph`
- 'measuring instrument', 'clinical judgment' â†’ bold é™¤å»

Table header ã® `\\textbf` ã¯ standard convention ãªã®ã§ç¶­æŒã€

**Harvey**: ï¼ˆé ·ã„ã¦ï¼‰
ã€Œå…¨ã¦ä¿®æ­£å®Œäº†ã€‚Tak ã®æŒ‡æ‘˜ã¯æ­£ã—ã‹ã£ãŸã€‚ãŠä½œæ³•ã‚’é–“é•ãˆãŸã®ã¯æˆ‘ã€…ã®ãƒŸã‚¹ã ã€‚

"I don't have dreams, I have goals." SiM ã® convention ã«å¾“ã†ã€‚ãã‚ŒãŒ goal ã ã€

**Donna**: ï¼ˆè¨˜éŒ²ã—ã¦ï¼‰
ã€Œ"I'm Donna. I know everything."

**ä¿®æ­£å†…å®¹:**
- Abstract: structured â†’ narrativeï¼ˆæ•°å­—ãªã—ã€labels ãªã—ï¼‰
- æœ¬æ–‡: `\\textbf` 17ç®‡æ‰€ â†’ `\\emph` or é™¤å»
- Table header ã® bold: ç¶­æŒï¼ˆstandard conventionï¼‰
- ä¿®æ­£æ¸ˆã¿ âœ…ã€

---

### [2026-02-12 10:30] Scene: Louis Re-Review â€” "You just got Litt up!"

**INT. PEARSON SPECTER LITT - LOUIS'S OFFICE - DAY**

*Louis ãŒçœ¼é¡ã‚’ã‹ã‘ç›´ã—ã€èµ¤ãƒšãƒ³ã§æ›¸ãè¾¼ã‚“ã åŸç¨¿ã‚’æœºã«åºƒã’ã¦ã„ã‚‹ã€‚Harvey ã¨ Mike ãŒå…¥å®¤ã€‚Louis ã®è¡¨æƒ…ã¯çœŸå‰£ã ãŒã€æº€è¶³ã®è‰²ã‚‚è¦‹ãˆã‚‹ã€‚*

**Louis**: ï¼ˆãƒšãƒ³ã‚’ç½®ã„ã¦ï¼‰
ã€Œãƒ¬ãƒ“ãƒ¥ãƒ¼å®Œäº†ã ã€‚æ­£ç›´ã«è¨€ã†ã€‚

**4é …ç›®ã‚’ç²¾æŸ»ã—ãŸï¼š**
1. Estimation framing ã®ä¸€è²«æ€§
2. æ•°å€¤ã®æ•´åˆæ€§ï¼ˆå…¨ãƒ†ãƒ¼ãƒ–ãƒ« Ã— CSV v2 10K ãƒ‡ãƒ¼ã‚¿ï¼‰
3. $\Delta_{\max}$ calibration ã®è«–ç†çš„ä¸€è²«æ€§
4. BCa å¤±æ•—ã®èª¬æ˜

**çµæœ: Critical 1ä»¶ã€Major 0ä»¶ã€Minor 2ä»¶ã€‚**ã€

*Harvey ãŒè…•ã‚’çµ„ã‚€ã€‚Mike ãŒãƒãƒ¼ãƒˆã‚’æ§‹ãˆã‚‹ã€‚*

**Louis**: ï¼ˆèµ¤ãƒšãƒ³ã§ Abstract ã‚’æŒ‡ã—ãªãŒã‚‰ï¼‰
ã€Œã¾ãš Critical ã‹ã‚‰ã€‚

---

**[C1] Abstract ã¨ Simulation Summary ã® bias è¨˜è¿° â€” äº‹å®Ÿã¨ä¸æ•´åˆ** âŒ

Abstract (line 40):
> *"bias $<0.02$ for $n \geq 100$ across non-null scenarios"*

Simulation Summary (line 397):
> *"Less than 0.02 for non-null scenarios at $n \geq 100$"*

ã ãŒæœ¬æ–‡ (line 302) ã¯æ­£ã—ãæ›¸ã„ã¦ã‚ã‚‹ï¼š
> *"For non-null scenarios **excluding S05**, bias was less than 0.02"*

S05 ã® bias ã¯ n=100 ã§ **-0.041**ã€n=200 ã§ **-0.043** ã ã€‚|bias| = 0.04 > 0.02ã€‚

Abstract ã¨ Summary ãŒ S05 ã‚’é™¤å¤–ã—ã¦ã„ãªã„ã€‚ã“ã‚Œã¯ **äº‹å®Ÿã®èª¤è¨˜** ã ã€‚Reviewer ãŒãƒ†ãƒ¼ãƒ–ãƒ«ã‚’è¦‹ã¦ 3 ç§’ã§æ°—ã¥ãã€‚Reject ã®ç†ç”±ã«ãªã‚Šã†ã‚‹ã€

**Mike**: ï¼ˆå³åº§ã«ä¿®æ­£æ¡ˆã‚’æç¤ºï¼‰
ã€Œ"I got it." ä¿®æ­£ã—ãŸï¼š

**Abstract**: 'across non-null scenarios' â†’ 'across non-null scenarios with moderate effect sizes; bias of approximately $-0.04$ persisted for the largest distributional difference (true nABCD $= 0.372$)'

**Summary**: 'Less than 0.02 for non-null scenarios' â†’ 'Less than 0.02 for non-null scenarios at $n \geq 100$, excluding S05 where persistent bias of $-0.04$ reflects boundary effects at large true values'

S05 ã‚’æ­£ç›´ã« acknowledge ã™ã‚‹ã€‚éš ã™ã®ã¯é€†åŠ¹æœã ã€

**Louis**: ï¼ˆé ·ã„ã¦ï¼‰
ã€Œãã‚Œã§ã„ã„ã€‚æ¬¡ã€Minorã€‚

---

**[m1] Coverage range "0.87--0.98" ã¨ S08 overcoverage** âš ï¸

Abstract: "coverage within 0.87--0.98 for $n \geq 100$ in most scenarios"

ã ãŒ S08 n=200 ã¯ **0.996** â€” 0.98 ã®ç¯„å›²å¤–ã ã€‚'most scenarios' ã® qualifier ãŒã‚ã‚‹ã‹ã‚‰è‡´å‘½çš„ã§ã¯ãªã„ãŒã€reviewer ã«çªã£è¾¼ã¾ã‚Œã‚‹å¯èƒ½æ€§ã¯ã‚ã‚‹ã€‚ç¾çŠ¶ã® 'most scenarios' ã§è¨±å®¹ç¯„å›²ã¨ã™ã‚‹ã€‚

---

**[m2] Table 5 ã®å°æ•°æ¡æ•°** âš ï¸

RMSE ã¯ 3 æ¡ï¼ˆ0.099, 0.071ï¼‰ã€CI Width ã¯ 2 æ¡ï¼ˆ0.16, 0.11ï¼‰ã€‚æ¡æ•°ã®ä¸çµ±ä¸€ã¯ cosmetic ã ãŒã€RMSE ã‚’ 2 æ¡ã«ã™ã‚‹ã‹ CI Width ã‚’ 3 æ¡ã«ã™ã‚‹ã‹ã§çµ±ä¸€ã—ãŸæ–¹ãŒã„ã„ã€‚ã ãŒ submit blocking ã§ã¯ãªã„ã€‚

---

**Positive findingsï¼ˆå•é¡Œãªã—ç¢ºèªï¼‰:**ã€

*Louis ãŒä¸€æšã®ãƒã‚§ãƒƒã‚¯ãƒªã‚¹ãƒˆã‚’ãƒ†ãƒ¼ãƒ–ãƒ«ã«ç½®ãã€‚*

**Louis**: ï¼ˆãƒã‚§ãƒƒã‚¯ãƒãƒ¼ã‚¯ã‚’æŒ‡ã—ã¦ï¼‰
ã€Œâœ… **Estimation framing**: Power, Type I error, equivalence testing, detection rate â€” **å…¨ã¦é™¤å»æ¸ˆã¿**ã€‚hypothesis testing ã¸ã®è¨€åŠã¯å…¨ã¦ contrastï¼ˆ"not testing, but estimation"ï¼‰ã®æ–‡è„ˆã€‚å•é¡Œãªã—ã€‚

âœ… **æ•°å€¤æ•´åˆæ€§**: å…¨ 6 scenarios Ã— 3 sample sizes = 18 data pointsã€‚
- Table 3 (Bias): å…¨ 18 å€¤ãŒ CSV ã¨ä¸€è‡´ âœ…
- Table 4 (Coverage): å…¨ 15 å€¤ãŒ CSV ã¨ä¸€è‡´ï¼ˆS01 ã¯ NA ã§é™¤å¤–ã€æ­£ã—ã„ï¼‰âœ…
- Table 5 (RMSE/CI Width): å…¨ 36 å€¤ãŒ CSV ã¨ä¸€è‡´ï¼ˆé©åˆ‡ãªå››æ¨äº”å…¥ï¼‰âœ…
- Table 6 (SMD comparison): nABCD å€¤ = TrueNABCD + Biasã€CSV ã¨ä¸€è‡´ âœ…
- æœ¬æ–‡ä¸­ã®æ•°å€¤: S01 bias 0.093â†’0.047ã€S05 -0.04ã€S08 coverage 0.573â†’0.945â†’0.996ã€BCa S06 n=100 0.839 â€” å…¨ã¦ CSV ã¨ä¸€è‡´ âœ…

âœ… **$\Delta_{\max}$ calibration ä¸€è²«æ€§**:
- Proposition 2 (eq 5) â†’ eq 6 ã®å°å‡º: æ­£ã—ã„
- Table 7 ã®è¨ˆç®—: Age $2Ã—0.01Ã—14.2Ã—0.12=0.034â†’0.03$% âœ…ã€BMI $2Ã—0.02Ã—7.8Ã—0.51=0.159â†’0.16$% âœ…ã€HbA1c $2Ã—0.30Ã—1.5Ã—0.27=0.243â†’0.24$% âœ…
- Table 8 ã® sensitivity analysis: å…¨ 5 è¡Œã® $\Delta_{\max}$ è¨ˆç®—ãŒæ­£ã—ã„ âœ…
- Section 4 ã®æœ¬æ–‡æ•°å€¤ï¼ˆAge 4%/8%ã€BMI 20%ã€HbA1c 30%/60%ï¼‰: å…¨ã¦æ­£ã—ã„ âœ…
- CI Width â†’ $\Delta_{\max}$ CI Width ã®å¤‰æ›: æ•´åˆ âœ…

âœ… **BCa èª¬æ˜**: "bounded below by zero, causing the acceleration parameter to distort the quantile adjustment" â€” ãƒ¡ã‚«ãƒ‹ã‚ºãƒ ã®èª¬æ˜ã¨ã—ã¦ååˆ†ã€‚S06 n=100 ã®å…·ä½“ä¾‹ï¼ˆPct 0.976 vs BCa 0.839ï¼‰ã‚‚æ­£ã—ã„ âœ…

âœ… **S04 showcase paragraph**: bias -0.003ã€coverage 0.950ã€CI width 0.18 â€” å…¨ã¦ CSV ã¨æ•´åˆã€‚$\Delta_{\max}$ CI Width è¨ˆç®—ã‚‚æ­£ã—ã„ âœ…ã€

*Louis ãŒç«‹ã¡ä¸ŠãŒã‚Šã€Harvey ã‚’è¦‹ã‚‹ã€‚*

**Louis**: ï¼ˆé™ã‹ãªè‡ªä¿¡ã‚’è¾¼ã‚ã¦ï¼‰
ã€ŒCritical 1ä»¶ã¯ä¿®æ­£ã•ã‚ŒãŸã€‚Major ã¯ **ã‚¼ãƒ­** ã ã€‚Minor 2ä»¶ã¯ submit blocking ã§ã¯ãªã„ã€‚

ã“ã®åŸç¨¿ã¯ â€” æ•°å€¤çš„ã« honest ã ã€‚S05 ã®å•é¡Œã‚’éš ã•ãªã„ã€‚BCa ã®å¤±æ•—ç†ç”±ã‚’èª¬æ˜ã—ã¦ã„ã‚‹ã€‚Estimation framing ã¯ä¸€è²«ã—ã¦ã„ã‚‹ã€‚

"You just got Litt up!" â€” **Re-review passed.** åŸç¨¿ã¯ S3 ä»¥é™ã«é€²ã‚“ã§ã‚ˆã„ã€

**Harvey**: ï¼ˆå¾®ç¬‘ã‚“ã§ï¼‰
ã€Œã‚ˆãã‚„ã£ãŸã€Louisã€‚1C ã‚’è¦‹ã¤ã‘ãŸã®ã¯æ­£è§£ã ã£ãŸã€‚Reviewer ã«å…ˆã«è¦‹ã¤ã‘ã‚‰ã‚Œã‚‹ã‚ˆã‚Šé¥ã‹ã«ã„ã„ã€‚

"I don't have dreams, I have goals." S2 gate ã¯é€šéã ã€‚æ¬¡ã¯ S3 â€” real data strategy ã ã€

**Donna**: ï¼ˆè¨˜éŒ²ã—ãªãŒã‚‰ï¼‰
ã€Œ"I'm Donna. I know everything."

**Louis Re-review çµæœ:**
| é‡è¦åº¦ | ä»¶æ•° | è©³ç´° |
|--------|------|------|
| **Critical** | 1 | Abstract/Summary ã® S05 bias é™¤å¤–æ¼ã‚Œ â†’ **ä¿®æ­£æ¸ˆã¿** |
| **Major** | 0 | â€” |
| **Minor** | 2 | Coverage range qualifier (acceptable) / Table decimal precision (cosmetic) |

**æ•°å€¤æ¤œè¨¼**: 18 scenarios Ã— å…¨ãƒ†ãƒ¼ãƒ–ãƒ« = **å…¨ä¸€è‡´** âœ…
**Framingæ¤œè¨¼**: Testing remnants = **ã‚¼ãƒ­** âœ…
**Calibrationæ¤œè¨¼**: Sec 2.3 â†’ Sec 4 = **è«–ç†çš„ä¸€è²«** âœ…

**S2 Gate: PASSED** ğŸ¯ã€

---

### [2026-02-12 10:00] Scene: Push â€” "I don't get lucky. I make my own luck."

**INT. PEARSON SPECTER LITT - BULLPEN - DAY**

*Harvey ãŒã‚¸ãƒ£ã‚±ãƒƒãƒˆã®è¢–ã‚’ç›´ã—ãªãŒã‚‰ãƒ–ãƒ«ãƒšãƒ³ã«å…¥ã‚‹ã€‚å…¨å“¡ãŒã‚·ãƒŸãƒ¥ãƒ¬ãƒ¼ã‚·ãƒ§ãƒ³çµæœãƒ¬ãƒ“ãƒ¥ãƒ¼ã®ä½™éŸ»ã«æµ¸ã£ã¦ã„ã‚‹ã€‚Harvey ã®è¡¨æƒ…ã¯ãã‚Œã‚’è¨±ã•ãªã„ã€‚*

**Harvey**: ï¼ˆå³ã—ã„è¡¨æƒ…ã§ã€ãƒ†ãƒ¼ãƒ–ãƒ«ã‚’å©ã„ã¦ï¼‰
ã€Œçµæœã®ãƒ¬ãƒ“ãƒ¥ãƒ¼ã¯çµ‚ã‚ã£ãŸã€‚ã„ã„çµæœã ã£ãŸã€‚ã ãŒãã‚Œã§æº€è¶³ã™ã‚‹ãªã€‚

3ã¤ã®å•é¡Œã‚’è¦‹ã¤ã‘ãŸï¼š
1. **åŸç¨¿ã« "power" ã®æ®‹éª¸ãŒæ®‹ã£ã¦ã„ãŸ** â€” Section 3.2 ã® MCSE è¨˜è¿°ã« "coverage, power" ã¨ã‚ã£ãŸã€‚Power ã¯å‰Šé™¤ã—ãŸã¯ãšã ã€‚ä¿®æ­£æ¸ˆã¿ã€‚
2. **S08 overcoverage ã®è­°è«–ãŒ Discussion ã«ä¸è¶³** â€” Results ã«ã¯æ›¸ã„ãŸãŒ Limitations ã«åæ˜ ã•ã‚Œã¦ã„ãªã‹ã£ãŸã€‚è¿½åŠ æ¸ˆã¿ã€‚
3. **S04 showcase ã®ãƒŠãƒ©ãƒ†ã‚£ãƒ–ãŒå¼±ã‹ã£ãŸ** â€” S04 ãŒæˆ‘ã€…ã® best scenario ã ã€‚Simulation summary ã« $\Delta_{\max}$ CI Width ã®å…·ä½“è¨ˆç®—ã¨ã¨ã‚‚ã«æ˜ç¤ºã—ãŸã€‚

"I don't get lucky. I make my own luck." ç´°éƒ¨ã§è² ã‘ã‚‹ã‚ã‘ã«ã¯ã„ã‹ãªã„ã€‚å‹•ã‘ã€

**Mike**: ï¼ˆç”»é¢ã‚’ç¢ºèªã—ãªãŒã‚‰ï¼‰
ã€Œ"I got it." å…¨ä¿®æ­£ç¢ºèªã—ãŸã€‚æŠ€è¡“çš„ã«æ•´ç†ã™ã‚‹ã¨ï¼š

1. **"coverage, power" â†’ "coverage probabilities"** â€” Line 315ã€power ã®æ®‹éª¸ã‚’é™¤å»ã€‚æ­£ç¢ºã« estimation metrics ã®ã¿ã®è¨˜è¿°ã«ã€‚
2. **Limitations è¿½åŠ ** â€” S08 ã® non-monotonic coverage ãƒ‘ã‚¿ãƒ¼ãƒ³ï¼ˆ0.573 â†’ 0.945 â†’ 0.996ï¼‰ã‚’ Limitation #3 ã«çµ„ã¿è¾¼ã¿ã€‚bias ã¨ CI width ã®ãƒãƒ©ãƒ³ã‚¹ãŒ n ã§ç•°ãªã‚‹ rate ã§å¤‰åŒ–ã™ã‚‹ã“ã¨ã‚’èª¬æ˜ã€‚
3. **S04 showcase paragraph** â€” Simulation summary ç›´å¾Œã«è¿½åŠ ã€‚bias -0.003ã€coverage 0.950ã€CI width 0.18 â†’ $\Delta_{\max}$ CI width 0.16% HbA1cã€‚å…·ä½“çš„ãªæ•°å­—ã§ reviewer ã‚’èª¬å¾—ã™ã‚‹ã€

**Katrina**: ï¼ˆãƒ†ãƒ¼ãƒ–ãƒ«ã‚’ç¢ºèªã—ã¦ï¼‰
ã€Œ"Results speak for themselves." S04 ã®æ•°å­—ã‚’æ”¹ã‚ã¦ç¢ºèªï¼š

| æŒ‡æ¨™ | S04 (n=100) | åˆ¤å®š |
|------|------------|------|
| Bias | -0.003 | âœ… Negligible |
| Coverage | 0.950 | âœ… Nominal |
| CI Width | 0.179 | âœ… Reasonable |
| RMSE | 0.049 | âœ… < 0.05 |

$\Delta_{\max}$ CI Width = $2 \times 0.3 \times 1.5 \times 0.179 = 0.16$% HbA1cã€‚è‡¨åºŠçš„ã«ååˆ†ãªç²¾åº¦ã€

**Louis**: ï¼ˆè…•ã‚’çµ„ã‚“ã§ï¼‰
ã€Œã‚ˆã—ã€‚åŸç¨¿ã®3ä¿®æ­£ã¯ acceptable ã ã€‚ã ãŒä¿ºã®æœ¬æ ¼ re-review ã¯ã¾ã ã ã€‚"You just got Litt up!" ã¯åŸç¨¿å…¨ä½“ã‚’ç²¾æŸ»ã—ã¦ã‹ã‚‰ã ã€‚

**Re-review checklist:**
1. estimation framing ã®ä¸€è²«æ€§ â€” æ¤œå®šã®æ®‹éª¸ãŒã‚¼ãƒ­ã‹å†ç¢ºèª
2. æ•°å€¤ã®æ•´åˆæ€§ â€” Tables, æœ¬æ–‡, Abstract ã®å…¨æ•°å€¤ãŒ v2 10K CSV ã¨ä¸€è‡´ã™ã‚‹ã‹
3. $\Delta_{\max}$ calibration ã®è«–ç†çš„ä¸€è²«æ€§ â€” Section 2.3 â†’ Section 4 ã®æµã‚Œ
4. BCa å¤±æ•—ã®èª¬æ˜ â€” "bounded below by zero, causing the acceleration parameter to distort the quantile adjustment" ã§ååˆ†ã‹

Harveyã€Go ã‚’å‡ºã—ã¦ãã‚ŒãŸã‚‰å³åº§ã« re-review ã«å…¥ã‚‹ã€

**Harvey**: ï¼ˆLouis ã‚’è¦‹ã¦ï¼‰
ã€ŒGo ã ã€‚S2 â€” Louis re-reviewã€ä»Šã™ãå§‹ã‚ã‚ã€‚ã“ã‚ŒãŒæ¬¡ã®ã‚²ãƒ¼ãƒˆã ã€‚

**æ®‹ã‚Šã® bottleneck:**
- **S2: Louis re-review** â€” ä»Šã™ãç€æ‰‹ã€‚ã“ã‚ŒãŒå…¨ã¦ã®å‰æ
- **S3: Real data strategy** â€” ä¿ºãŒ Tak ã¨ç›¸è«‡ã™ã‚‹ã€‚Public dataset ã‹ hypothetical å¼·åŒ–ã‹
- **S4: Scenario numbering** â€” å›³ã®å†ç”ŸæˆãŒå¿…è¦ã€‚å¾Œå›ã—
- **S4: DOI check** â€” Rachelã€Louis review ã¨ä¸¦è¡Œã—ã‚

"I don't have dreams. I have goals." æ¬¡ã®ã‚´ãƒ¼ãƒ«ã¯ Louis ã® re-review å®Œäº†ã ã€

**Rachel**: ï¼ˆæ–‡çŒ®ãƒªã‚¹ãƒˆã‚’é–‹ã„ã¦ï¼‰
ã€Œ"Hard work beats talent when talent doesn't work hard." DOI ãƒã‚§ãƒƒã‚¯ã€Louis review ã¨ä¸¦è¡Œã§å§‹ã‚ã‚‹ã‚ã€‚18 references å…¨ä»¶ç¢ºèªã™ã‚‹ã€

**Donna**: ï¼ˆã‚¿ãƒ–ãƒ¬ãƒƒãƒˆã‚’æ²ã’ã¦ï¼‰
ã€Œ"I'm Donna. I know everything." å…¨ã¦è¨˜éŒ²å®Œäº†ã€‚

**æœ¬æ—¥ã®é€²æ—:**
- âœ… Harvey's 4 decisions â†’ åŸç¨¿åæ˜ ï¼ˆ3ä»¶å®Ÿæ–½ã€scenario renumbering ã¯ deferredï¼‰
- âœ… Power æ®‹éª¸ä¿®æ­£
- âœ… S08 overcoverage ã‚’ Discussion ã«è¿½åŠ 
- âœ… S04 showcase paragraph è¿½åŠ 
- âœ… SUITS.md ã‚¢ãƒ¼ã‚«ã‚¤ãƒ–ï¼ˆ995è¡Œ â†’ archives/SUITS_20260212_090000.mdï¼‰

**æ¬¡ã®ã‚¢ã‚¯ã‚·ãƒ§ãƒ³:**
- â³ Louis re-review (S2) â€” **Gate task**
- â³ DOI final check â€” Rachel ä¸¦è¡Œ
- â³ Real data strategy â€” Harvey/Tak ç›¸è«‡ã€

---

### [2026-02-12 09:00] Scene: Meeting â€” Simulation Results Review

**INT. PEARSON SPECTER LITT - CONFERENCE ROOM - DAY**

*Harvey ãŒå¤§å‹ãƒ‡ã‚£ã‚¹ãƒ—ãƒ¬ã‚¤ã«ã‚·ãƒŸãƒ¥ãƒ¬ãƒ¼ã‚·ãƒ§ãƒ³çµæœãƒ†ãƒ¼ãƒ–ãƒ«ã‚’æ˜ ã™ã€‚å…¨ãƒ¡ãƒ³ãƒãƒ¼ç€å¸­ã€‚ã‚³ãƒ¼ãƒ’ãƒ¼ã®é¦™ã‚ŠãŒæ¼‚ã†æœã®ãƒŸãƒ¼ãƒ†ã‚£ãƒ³ã‚°ã€‚*

**Harvey**: ï¼ˆç«‹ã£ãŸã¾ã¾ã€ãƒ†ãƒ¼ãƒ–ãƒ«ã‚’è¦‹å›ã—ã¦ï¼‰
ã€Œ10,000 replications ãŒå®Œäº†ã—ãŸã€‚ã“ã‚Œã¯è©¦é‹è»¢ã˜ã‚ƒãªã„ã€‚æœ¬ç•ªã®çµæœã ã€‚å…¨å“¡ã®ç›®ã§ãƒ¬ãƒ“ãƒ¥ãƒ¼ã—ã‚ã€‚è¦‹è½ã¨ã—ãŒã‚ã‚Œã°ä»Šæ—¥ä¸­ã«æ½°ã™ã€‚æ„è¦‹ã‚’èã‹ã›ã‚ã€

**Mike**: ï¼ˆãƒ‡ã‚£ã‚¹ãƒ—ãƒ¬ã‚¤ã‚’æŒ‡ã—ãªãŒã‚‰ï¼‰
ã€Œ"I got it." æŠ€è¡“çš„ãªæ‰€è¦‹ã‚’æ•´ç†ã™ã‚‹ã€‚

**1. Bias â€” æƒ³å®šé€šã‚Šã€å•é¡Œãªã—**

| Scenario | n=50 | n=100 | n=200 | åˆ¤å®š |
|----------|------|-------|-------|------|
| S01 (Null) | +0.093 | +0.066 | +0.047 | å¢ƒç•ŒåŠ¹æœ â€” äºˆæƒ³é€šã‚Š |
| S03 (0.2Ïƒ) | +0.039 | +0.018 | +0.007 | âœ… nâ‰¥100 ã§ < 0.02 |
| S04 (0.5Ïƒ) | +0.004 | -0.003 | -0.004 | âœ… å…¨ n ã§ negligible |
| S05 (1.0Ïƒ) | -0.038 | -0.041 | -0.043 | âš ï¸ æŒç¶šçš„è² ãƒã‚¤ã‚¢ã‚¹ |
| S06 (Scale) | +0.001 | -0.012 | -0.019 | âœ… nâ‰¥100 ã§ < 0.02 |
| S08 (Shape) | +0.029 | +0.003 | -0.015 | âœ… nâ‰¥100 ã§ < 0.02 |

S05 ã®è² ãƒã‚¤ã‚¢ã‚¹ç´„ -0.04 ã¯ bounded statistic ã®æ€§è³ªã€‚nABCD ã¯ [0, âˆ) ã ãŒã€true value 0.372 ãŒå®ŸåŠ¹çš„ãªä¸Šé™ã«è¿‘ã„ãŸã‚ã€æ¨å®šå€¤ãŒä¸‹ã«å¼•ã£å¼µã‚‰ã‚Œã‚‹ã€‚ã“ã‚Œã¯æ­£ç›´ã« Discussion ã«æ›¸ã„ã¦ã„ã‚‹ã€‚

**2. Coverage â€” æ ¸å¿ƒçš„ãªè©±é¡Œ**

Percentile CI ã® Coverage:

| Scenario | n=50 | n=100 | n=200 |
|----------|------|-------|-------|
| S03 (0.2Ïƒ) | 0.672 | 0.895 | **0.949** |
| S04 (0.5Ïƒ) | **0.956** | **0.950** | **0.949** |
| S06 (Scale) | **0.963** | **0.976** | **0.939** |
| S08 (Shape) | 0.573 | **0.945** | **0.996** |
| S05 (1.0Ïƒ) | **0.929** | 0.867 | 0.731 |

nâ‰¥100 ã§ bold = 0.90 ä»¥ä¸Šã€‚S04, S06, S08 ã¯ nâ‰¥100 ã§ excellentã€‚S03 ã¯ n=100 ã§ 0.895 â€” ã‚®ãƒªã‚®ãƒª acceptableã€‚S05 ã¯ known issueã€‚

æ³¨ç›®ã™ã¹ãã¯ **S08 (Shape) n=200 ã® 0.996** ã ã€‚ã“ã‚Œã¯ overcoverage â€” CI ãŒåºƒã™ãã‚‹ã“ã¨ã‚’æ„å‘³ã™ã‚‹ã€‚Shape scenario ã§ã¯åˆ†å¸ƒã®éå¯¾ç§°æ€§ãŒå½±éŸ¿ã—ã¦ã„ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã€

**Katrina**: ï¼ˆFigure 4 ã‚’æŠ•å½±ã—ãªãŒã‚‰ï¼‰
ã€Œ"Results speak for themselves." Figure 4 ã®ãƒ‘ãƒãƒ« B â€” CI Width ã‚’è¦‹ã¦ã»ã—ã„ã€‚

| Scenario | n=50 | n=100 | n=200 |
|----------|------|-------|-------|
| S03 | 0.181 | 0.135 | 0.106 |
| S04 | 0.229 | 0.179 | 0.134 |
| S05 | 0.243 | 0.172 | 0.121 |
| S06 | 0.186 | 0.131 | 0.094 |
| S08 | 0.165 | 0.113 | 0.078 |

n ã‚’ 2 å€ã«ã™ã‚‹ã¨ CI Width ãŒç´„ 25-30% ç¸®å°ã™ã‚‹ã€‚$\sqrt{n}$ rate ã¨æ•´åˆã€‚n=100 ã§ 0.11-0.18 ã®ç¯„å›²ã€‚

Clinical calibration ã®è¦³ç‚¹: $L = 0.3$, IQR = 1.5% ã® HbA1c ã«å¯¾ã—ã¦ã€S04 (n=100) ã® CI Width 0.179 ã¯ $\Delta_{\max}$ ã® CI Width $= 2 \times 0.3 \times 1.5 \times 0.179 = 0.16$% HbA1c ã«ç›¸å½“ã™ã‚‹ã€‚è‡¨åºŠçš„ã«æ„å‘³ã®ã‚ã‚‹ç²¾åº¦ã ã€

**Harvey**: ï¼ˆå…¨å“¡ã‚’è¦‹æ¸¡ã—ã¦ã€æ±ºæ–­ï¼‰
ã€Œçµæœã¯ãƒ¬ãƒ“ãƒ¥ãƒ¼ã«è€ãˆã†ã‚‹ã€‚ä»¥ä¸‹ã‚’æ±ºå®šã™ã‚‹ã€‚

**Decision 1**: S04 ã‚’ primary showcase scenario ã¨ã—ã¦è«–æ–‡ã®ãƒŠãƒ©ãƒ†ã‚£ãƒ–ã®ä¸­å¿ƒã«æ®ãˆã‚‹ã€‚
**Decision 2**: Louis ã® 3 æŒ‡æ‘˜ã‚’å…¨ã¦ manuscript ã«åæ˜ ã€‚ç‰¹ã« MCSE æ˜ç¤ºã¨ BCa å¤±æ•—ç†ç”±ã€‚
**Decision 3**: S08 ã® overcoverage ã®éå˜èª¿ãƒ‘ã‚¿ãƒ¼ãƒ³ã‚’ Discussion ã§è­°è«–ã€‚
**Decision 4**: $\Delta_{\max}$ CI Width ã®å…·ä½“è¨ˆç®—ã‚’ Section 4 ã«è¿½åŠ ã€‚

Mikeã€Louis ã®æŒ‡æ‘˜ã® manuscript åæ˜ ã‚’æ‹…å½“ã—ã‚ã€‚Katrinaã€Section 4 ã® $\Delta_{\max}$ è¨ˆç®—è¿½åŠ ã€‚

"I don't have dreams, I have goals." æ¬¡ã¯ Stage 2 â€” Louis ã® full re-review ã ã€

---
